il-15
Lung Cancer (Diagnosis)
Essen BiotechPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
67 Active assets in the Lung Cancer (Diagnosis) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Taiho Oncology, Inc. | Phase 3 | BB |
OTL-38 On Target Laboratories, LLC | Phase 4 | BB |
ETOPOSIDE SystImmune Inc. | Phase 3 | BB |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | B |
Carboplatin SystImmune Inc. | Phase 3 | B |
View all 50 →
Same molecule, other indications
il-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →